Considering that CD3E was obviously under-expression in EC than non-EC patients (61.5% vs. 0%, P = 0.082), especially in MSS patients, application of CD3-BsAb in the treatment of MSS EC deserves more research. This evidence concerns the gene CD3E and Marinesco-Sjogren syndrome.